Moreover, the angiotensin II inhibitor losartan also displays the ability to decrease collagen and HA production by inhibiting TGFβ, connective tissue growth factor (CTGF), and endothelin-1 (ET-1) profibrotic signals, and consequently improves drug and oxygen delivery to tumors, thereby potentiating chemotherapy and reducing hypoxia in breast and pancreatic cancer models [281]. Here, EDN1 is linked to pancreatic neoplasm.